Here's How Charles River Stock Is Placed Ahead of Q4 Earnings

Key Takeaways CRL is set to report Q4 results on Feb. 18, with revenues and EPS expected to decline year over year. Charles River's RMS may see modest growth, aided by Noveprim and GEMS momentum. CRL's DSA revenues may fall on biotech budget pressure, while Manufacturing shows steady gains. Charles River Laboratories International, Inc. (CRL) is scheduled to report fourth-quarter 2025 results on Feb. 18, before the market opens.In the last reported quarter, the company’s adjusted earnings per share (EPS) of ...